GW Pharmaceuticals plc GWPH said Monday it will obtain exclusive rights for the commercialization of Sativex in the U.K. from Bayer AG BAYRY.
Sativex is an oromucosal spray with the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 1-to-1 ratio.
In the U.S. it is known under the name Nabiximols and is used to help treat spasticity in patients suffering from multiple sclerosis.
The spray was approved by the Medicines and Healthcare products Regulatory Agency back in 2010, and Bayer has seen controlled advertising in the U.K.
GW Pharma will obtain all duties regarding the commercialization of Sativex in the U.K., after the end of the year, and will be in a transitional period until then, according to the company.
GW Pharma’s shares were trading lower by at $100.78 at the time of publication Monday.
Related Links:
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!